Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

This study evaluates the safety, efficacy, and health economic outcomes of modular robotic-assisted minimally invasive esophagectomy (RAMIE) compared with conventional thoracoscopic minimally invasive esophagectomy (MIE) in patients with resectable esophageal cancer. Participants are randomly assigned in a 1:1 ratio to undergo either modular robotic-assisted esophagectomy using the Carina™ Surgical Platform (experimental group) or conventional thoracoscopic esophagectomy (control group). The primary endpoint is the rate of Textbook Outcome (TO) within 30 days post-operation. Secondary endpoin

Trial Details

NCT ID
NCT07888140
Phase
PHASE3
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Modular Robot-Assisted Esophagectomy
  • Conventional Minimally Invasive Esophagectomy
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥18 years, regardless of sex;
  • Histologically confirmed resectable malignant esophageal tumor, without invasion of adjacent vital organs and without evidence of distant metastasi…
  • Patients may have received neoadjuvant therapy;
  • Willing and able to provide written informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →